204 related articles for article (PubMed ID: 35794067)
1. Efficacy and safety of intravenous OPC-61815 compared with oral tolvaptan in patients with congestive heart failure.
Sato N; Uno S; Kurita Y; Kim S;
ESC Heart Fail; 2022 Oct; 9(5):3275-3286. PubMed ID: 35794067
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tolvaptan for Intravenous Administration, in Patients With Congestive Heart Failure - A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial.
Sato N; Uno S; Yamasaki Y; Hirano T; Kim S;
Circ J; 2022 Mar; 86(4):699-708. PubMed ID: 34511586
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
Matsuzaki M; Hori M; Izumi T; Fukunami M;
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S33-45. PubMed ID: 22120092
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tolvaptan in heart failure patients with sustained volume overload despite the use of conventional diuretics: a phase III open-label study.
Fukunami M; Matsuzaki M; Hori M; Izumi T;
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S47-56. PubMed ID: 22120093
[TBL] [Abstract][Full Text] [Related]
5. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
[TBL] [Abstract][Full Text] [Related]
6. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
[TBL] [Abstract][Full Text] [Related]
7. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
Gheorghiade M; Konstam MA; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
JAMA; 2007 Mar; 297(12):1332-43. PubMed ID: 17384438
[TBL] [Abstract][Full Text] [Related]
8. [The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia].
Li L; Bai H; Zhu WL;
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):936-40. PubMed ID: 22321279
[TBL] [Abstract][Full Text] [Related]
9. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.
Hanatani A; Shibata A; Kitada R; Iwata S; Matsumura Y; Doi A; Sugioka K; Takagi M; Yoshiyama M
Heart Vessels; 2017 Mar; 32(3):287-294. PubMed ID: 27385022
[TBL] [Abstract][Full Text] [Related]
10. Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Matsuzaki M; Hori M; Izumi T; Asanoi H; Tsutamoto T;
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S19-31. PubMed ID: 22120091
[TBL] [Abstract][Full Text] [Related]
11. Tolerability of the Intravenously Administered Tolvaptan Prodrug, OPC-61815, in Patients With Congestive Heart Failure Who Have Difficulty With, or Are Incapable of, Oral Intake (TRITON-HF) - A Phase III, Multicenter, Open-Label Trial.
Kinugawa K; Nakata E; Hirano T; Kim S
Circ J; 2022 Jun; 86(7):1068-1078. PubMed ID: 35264514
[TBL] [Abstract][Full Text] [Related]
12. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tolvaptan for pediatric patients with congestive heart failure. Multicenter survey in the working group of the Japanese Society of PEdiatric Circulation and Hemodynamics (J-SPECH).
Higashi K; Murakami T; Ishikawa Y; Itoi T; Ohuchi H; Kodama Y; Honda T; Masutani S; Yamazawa H; Senzaki H; Ishikawa S
Int J Cardiol; 2016 Feb; 205():37-42. PubMed ID: 26710331
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure.
Felker GM; Mentz RJ; Cole RT; Adams KF; Egnaczyk GF; Fiuzat M; Patel CB; Echols M; Khouri MG; Tauras JM; Gupta D; Monds P; Roberts R; O'Connor CM
J Am Coll Cardiol; 2017 Mar; 69(11):1399-1406. PubMed ID: 27654854
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of oral tolvaptan in patients undergoing hemodialysis: a Phase 2, double-blind, randomized, placebo-controlled trial.
Ogata H; Shimofurutani N; Okada T; Nagamoto H; Akizawa T
Nephrol Dial Transplant; 2021 May; 36(6):1088-1097. PubMed ID: 32901255
[TBL] [Abstract][Full Text] [Related]
16. Impact of urine cyclic AMP relative to plasma arginine vasopressin on response to tolvaptan in patients with chronic kidney disease and heart failure.
Kakeshita K; Koike T; Imamura T; Fujioka H; Yamazaki H; Kinugawa K
Clin Exp Nephrol; 2023 May; 27(5):427-434. PubMed ID: 36752971
[TBL] [Abstract][Full Text] [Related]
17. Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide.
Suzuki S; Yoshihisa A; Yamaki T; Sugimoto K; Kunii H; Nakazato K; Abe Y; Saito T; Ohwada T; Suzuki H; Saitoh S; Kubota I; Takeishi Y;
J Clin Pharmacol; 2013 Dec; 53(12):1277-85. PubMed ID: 24142853
[TBL] [Abstract][Full Text] [Related]
18. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y
Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
[TBL] [Abstract][Full Text] [Related]
19. Tolvaptan vs. furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF).
Ng TMH; Grazette LP; Fong MW; Yoon AJ; Lou M; Kuo A; Upadhyay RY; Han EE; Mehra A; Elkayam U
ESC Heart Fail; 2020 Aug; 7(4):1927-1934. PubMed ID: 32543020
[TBL] [Abstract][Full Text] [Related]
20. Effects of Tolvaptan on Volume Overload in Patients with Heart Failure.
Kinugawa K; Sato N; Inomata T
Int Heart J; 2018 Nov; 59(6):1368-1377. PubMed ID: 30369583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
